WARF: P170288US01

  • Assigned to WARF as biological material.

Titin Minigene: Cardiac Research Tool


Marion Greaser, Shijun Li, Wei Guo

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in a minigene construct of the titin gene that can be used for cardiac drug research and other applications.
OVERVIEWTitin is a sarcomeric protein expressed primarily in striated muscles. It is responsible for maintaining the structure and biomechanical properties of muscle cells.

In the heart, cardiac titin undergoes developmental size reduction from neonate to adulthood. This reduction results from gradually increased exon skipping between exons 50 and 219 of titin mRNA. UW–Madison researchers and collaborators previously identified Rbm20 as the splicing factor responsible for this process.
THE INVENTIONTo study the mechanisms of Rbm20-mediated exome skipping, the researchers have produced a number of minigene constructs (described in Li 2013). The construct comprises exons 64-70 of the titin gene.
  • Cardiac drug research tool
  • Available as a biomaterial
For More Information About the Inventors
  • Li S., Guo W., Dewey C.N. and Greaser M.L. 2013. Rbm20 Regulates Titin Alternative Splicing as a Splicing Repressor. Nucleic Acids Res. 41, 2659–2672.
Contact Information
For current licensing status, please contact Jennifer Gottwald at or 608-960-9854.
The WARF Advantage

Since its founding in 1925 as the patenting and licensing organization for the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.